Staff Reports
Secretary of Defense Pete Hegseth announced this week a new Department of Defense policy: annual testosterone testing for service members age 30 and older, added to the routine periodic health assessment. He says it is about readiness and long‑term health, and that treatment is voluntary. That is the news — plain and simple — and it deserves a clear, conservative take: we should back anything that honestly improves readiness, but we should insist on medical standards, transparency, and common sense before rolling it out across the force.
What Hegseth actually ordered
The policy Hegseth announced requires annual screening for “testosterone deficiency” for troops 30 and up, with voluntary tests for younger service members. If a clinician recommends testosterone replacement therapy (TRT), service members can accept or refuse treatment. That is a straightforward readiness argument: keep our troops in peak physical and mental shape. The Department of Defense framed this as a health measure, not a performance enhancement program, and that distinction matters — especially in a military that already wrestles with fitness, mental health, and deployment tempo.
Medical standards and real questions the Pentagon still must answer
Doctors and clinical societies have raised sensible concerns. Good medical practice usually tests men only when they have symptoms, confirms low testosterone with repeat early‑morning blood draws, and watches for fertility, blood‑viscosity, and cardiac risks before starting TRT. The Pentagon has not yet released the implementing memo or clinical protocol — so we don’t know whether DoD will follow those steps or take shortcuts. Before ordering mass annual blood draws, the Defense Department should publish the protocol, explain lab timing and confirmation rules, spell out monitoring and fertility counseling, and show the cost and capacity estimates for military hospitals and TRICARE.
Politics, optics, and predictable pushback
Predictably, some Democratic lawmakers and left‑leaning commentators mocked the move or called it “gender‑affirming care,” even as others urged extending hormone screening to women for fertility reasons. That’s either political theater or confused policy debate — probably a bit of both. Conservatives who value readiness should not let petty culture‑war sniping distract from practical concerns. If this policy truly boosts lethality, reduces long‑term health problems, and is carried out under proper medical rules, it’s worth trying. If it becomes a way to micromanage personnel or to strip privacy from troops, it must be stopped.
Bottom line: back readiness, demand oversight
Secretary of Defense Pete Hegseth is right to look for practical ways to keep our force healthy and ready. But conservatives who support a strong military should insist on evidence, guardrails, and oversight. The next step is simple: the Pentagon must publish the implementing guidance, answer questions from military doctors and Congress, and show that screening will not harm deployability, fertility, or privacy. Do that, and troops win — along with taxpayers and national security. Skip it, and we’ll get politics and clinics running the show instead of medicine and mission.
